These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2751430)

  • 21. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells.
    Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G
    Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection.
    Sugaya N; Kimura H; Hara S; Hoshino Y; Kojima S; Morishima T; Tsurumi T; Kuzushima K
    J Infect Dis; 2004 Sep; 190(5):985-8. PubMed ID: 15295706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxicity of bovine lymphocytes after treatment with lymphokines.
    Campos M; Rossi CR
    Am J Vet Res; 1986 Jul; 47(7):1524-8. PubMed ID: 3488701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.
    Boyer PJ; Berek JS; Zighelboim J
    Obstet Gynecol; 1989 May; 73(5 Pt 1):793-7. PubMed ID: 2784847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2',5'-Oligoadenylate trimer core and the cordycepin analog augment the tumoricidal activity of human natural killer cells.
    Black PL; Henderson EE; Pfleiderer W; Charubala R; Suhadolnik RJ
    J Immunol; 1984 Nov; 133(5):2773-7. PubMed ID: 6332860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of stimulation of natural killer-cell cytotoxicity by interferon and an interferon-inducer in the rat.
    Flexman JP; Shellam GR
    Immunology; 1981 Oct; 44(2):311-20. PubMed ID: 6170575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.
    Vie H; Bonneville M; Sondermeyer P; Moreau JF; Soulillou JP
    Immunology; 1986 Mar; 57(3):351-7. PubMed ID: 3082744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased cell-free viral DNA in fatal cases of chronic active Epstein-Barr virus infection.
    Kanegane H; Wakiguchi H; Kanegane C; Kurashige T; Miyawaki T; Tosato G
    Clin Infect Dis; 1999 Apr; 28(4):906-9. PubMed ID: 10825059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection.
    Ohga S; Nomura A; Takada H; Ihara K; Kawakami K; Yanai F; Takahata Y; Tanaka T; Kasuga N; Hara T
    J Infect Dis; 2001 Jan; 183(1):1-7. PubMed ID: 11106535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study: evaluation of the antibody-dependent cell-mediated cytotoxicity assay in chronic active Epstein-Barr syndrome.
    Waters-Peacocke N; Wray BB; Ades EW
    J Clin Lab Immunol; 1988 Sep; 27(1):11-2. PubMed ID: 2855078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.
    Ueno Y; Miyawaki T; Seki H; Matsuda A; Taga K; Sato H; Taniguchi N
    J Immunol; 1985 Jul; 135(1):180-4. PubMed ID: 3923100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus load in cerebrospinal fluid of patients with chronic active Epstein-Barr virus infection.
    Ohga S; Sanefuji M; Ishimura M; Nomura A; Torisu H; Kira R; Takada H; Mizuno Y; Kazuyama Y; Hara T
    Pediatr Infect Dis J; 2008 Nov; 27(11):1027-30. PubMed ID: 18833029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
    Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
    Lotz M; Tsoukas CD; Fong S; Dinarello CA; Carson DA; Vaughan JH
    J Immunol; 1986 May; 136(10):3636-42. PubMed ID: 3009608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
    Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
    J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonality analysis by sequence variation of the latent membrane protein 1 gene in patients with chronic active Epstein-Barr virus infection.
    Shibata Y; Hoshino Y; Hara S; Yagasaki H; Kojima S; Nishiyama Y; Morishima T; Kimura H
    J Med Virol; 2006 Jun; 78(6):770-9. PubMed ID: 16628581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.